Essential to increase the use of generics in Europe to maintain comprehensive health care?

Essential to increase the use of generics in Europe to maintain comprehensive health care?

Authors

  • Brian Godman Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
  • Marion Bennie Strathclyde Institute for Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom 5 Information Services Division, NHS National Services Scotland, Edinburgh, United Kingdom, EH12 9EB
  • Christoph Baumgärtel Austrian Medicines and Medical Devices Agency, Traisengasse 5, Wien, Austria
  • Ljiljana Sović-Brkičić Department of Drugs and Medical Products, Croatian Institute for Health Insurance, Zagreb, Croatia
  • Thomas Burkhardt Hauptverband der Österreichischen Sozialversicherungsträger, Kundmanngasse 21, Wien, Austria
  • Jurij Fürst Health Insurance Institute, Ljubljana, Slovenia
  • Kristina Garuoliene Medicines Reimbursement Department, National Health Insurance Fund, Vilnius, Lithuania
  • Miguel Gomes INFARMED, Parque da Saúde de Lisboa, Lisboa, Portugal
  • Vanda Markovic-Pekovic Faculty of Medicine, University of Banja Luka, Banja Luka, Republic Srpska, Bosnia and Herzegovina Ministry of Health and Social Welfare, Banja Luka, Republic Srpska, Bosnia and Herzegovina
  • Andrew Martin NHS Bury, Bury, UK
  • Catherine Sermet IRDES, 10, rue Vauvenargues, 75018, Paris, France
  • Peter Skiold Dental and Pharmaceuticals Benefits Agency (TLV), Stockholm, Sweden
  • Menno van Woerkom Dutch Institute for Rational Use of Medicines, 3527 Utrecht, Netherlands
  • Luka Voncina Ministry of Health, Republic of Croatia, Zagreb, Croatia
  • Lars L. Gustafsson Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden

DOI:

https://doi.org/10.7175/fe.v13i3S.312

Keywords:

Demand-Side Measures, Europe, Generics, Pharmaceuticals, Pricing, Supply-Side Measures

Abstract

INTRODUCTION: Reforms have been introduced across Europe to increase prescribing efficiency with existing drugs. These include measures to lower prices of generics as well as increase their prescribing versus originators and patented products in a class or related class. This is essential to maintain comprehensive health care in Europe given continued pressures. The alternative is insufficient funds for new innovative drugs and increasing drug volumes with ageing populations. OBJECTIVE: To review the influence of measures and initiatives to increase the prescribing and dispensing of generics at low prices on ambulatory care prescribing efficiency. In view of this, provide guidance as authorities strive to introduce further reforms to meet their goals. METHODOLOGY: A narrative review of published papers combined with case histories. RESULTS: The different supply- and demand-side measures have reduced generic prices to as low as 2% to 3% of pre-patent loss prices in some cases as well as appreciably enhanced their utilisation. As a result, prescribing efficiency has increased without compromising care. In some cases, the reforms have led to expenditure actually falling despite appreciably increased volumes. CONCLUSIONS: Increasing use of generics at low prices will help maintain the European ideals of comprehensive and equitable health care. However, countries will continually need to learn from each other.

Downloads

Published

2012-12-05

How to Cite

Godman, B., Bennie, M., Baumgärtel, C., Sović-Brkičić, L., Burkhardt, T., Fürst, J., … Gustafsson, L. L. (2012). Essential to increase the use of generics in Europe to maintain comprehensive health care?. Farmeconomia. Health Economics and Therapeutic Pathways, 13(3S), 5–20. https://doi.org/10.7175/fe.v13i3S.312

Issue

Section

Review (Economic Analysis)

Similar Articles

<< < 1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.

Loading...